Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

T Cell Activation and Clonal Selection

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Efficacy of post-transplant brentuximab vedotin maintenance by pre-transplant disease status in relapsed/refractory classic Hodgkin lymphoma.

Blood cancer journal·2026

Same author

Neighborhood Socioeconomic Disadvantage and Distance From Treatment Center do not Impact Survival Outcomes of Patients With Non-Hodgkin Lymphoma and Multiple Myeloma Treated With CAR T-Cell Therapies.

Transplantation and cellular therapy·2026

Same author

EBV-Negative Post-Lung Transplant Lymphoma Diagnosed via Paracentesis: A Case Report and Literature Review.

Case reports in transplantation·2026

Same author

Odronextamab in people with relapsed or refractory follicular lymphoma: plain language summary of the ELM-2 study.

Future oncology (London, England)·2026

Same author

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Blood cancer journal·2026

Same author

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Blood advances·2026

Same journal

BRAF Alterations in Chronic Lymphocytic Leukemia: Genomic Landscape, Co-Mutation Patterns, and Clinical Relevance.

Current hematologic malignancy reports·2026

Same journal

Targeting the BCR::ABL1 Kinase: Advances Beyond Imatinib in Chronic Myeloid Leukemia.

Current hematologic malignancy reports·2026

Same journal

Germline DDX41 Variants: Current Understanding and Future Directions.

Current hematologic malignancy reports·2026

Same journal

Clonal Signatures of Telomere Biology Disorders.

Current hematologic malignancy reports·2026

Same journal

Molecular Pathogenesis and Targeted Therapies for Myeloproliferative Hypereosinophilic Neoplasms.

Current hematologic malignancy reports·2026

Same journal

The Intricate Dance Between Inflammation and Myeloproliferative Neoplasms: From Origins to Outcomes.

Current hematologic malignancy reports·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Mar 11, 2026

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

Enteropathy-Associated T-Cell Lymphoma.

Sarah Ondrejka¹, Deepa Jagadeesh²

¹Pathology and Laboratory Medicine Institute, Cleveland Clinic, 9500 Euclid Ave, L-30, Cleveland, OH, 44195, USA.

Current Hematologic Malignancy Reports

|December 1, 2016

Summary

This summary is machine-generated.

Enteropathy-associated T-cell lymphoma, a rare intestinal cancer linked to celiac disease, presents aggressively. Combination chemotherapy and stem cell transplant offer hope, but novel therapies are needed for better outcomes.

Keywords:

Celiac disease Intestinal T-cell lymphoma Monomorphic CD56+ intestinal T-cell lymphoma Refractory celiac disease, monomorphic epitheliotropic intestinal T-cell lymphoma Type I enteropathy-associated T-cell lymphoma Type II enteropathy-associated T-cell lymphoma

More Related Videos

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Related Experiment Videos

Last Updated: Mar 11, 2026

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants

Published on: August 9, 2019

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

Area of Science:

Gastroenterology
Oncology
Immunology

Background:

Enteropathy-associated T-cell lymphoma (EATL) is a rare intestinal neoplasm.
It is strongly associated with celiac disease and presents aggressively.
Clinical manifestations range from malabsorption to abdominal emergencies.

Purpose of the Study:

To review the clinicopathologic features of EATL.
To discuss current treatment strategies and outcomes.
To highlight the need for novel therapeutic approaches.

Main Methods:

Review of existing literature on EATL.
Analysis of epidemiological and clinicopathologic data.
Evaluation of treatment outcomes from collective experience.

Main Results:

EATL is characterized by aggressive behavior and association with celiac disease.
WHO classification historically divided EATL into types I and II, with ongoing debate on their separation.
Combination chemotherapy followed by autologous hematopoietic stem cell transplant shows favorable outcomes in select patients.

Conclusions:

Despite treatment advances, the prognosis for EATL remains poor.
Low incidence and patient variability hinder clinical trials and standard treatment development.
Further research is crucial to identify effective novel therapies for EATL.